Role of Fetuin-A in the Pathogenesis of Psoriasis and Its Potential Clinical Applications

References

• Kettler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentration in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361(9360):827–833. doi:10.1016/S0140-6736(03)12710-9
   PubMed Web of Science ®Google Scholar
• Wojtysiak-Duma B, Malecha Jędraszek A, Burska A, et al. Serum fetuin-A levels in patients with type 2 diabetes mellitus. Ann UMCS Sect. 2010;1500:2.
   Google Scholar
• Mori K, Emoto M, Yokoyama H, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care. 2006;29(2):468. doi:10.2337/diacare.29.02.06.dc05-1484
   PubMed Web of Science ®Google Scholar
• Osawa M, Umetsu K, Sato M, et al. Structure of the gene encoding human alpha2-HS glycoprotein (AHSG). Gene. 1997;196(1–2):121–125. doi:10.1016/S0378-1119(97)00216-3
   PubMed Web of Science ®Google Scholar
• Dietzel E, Wessling J, Floehr J, et al. Fetuin-B, a liver-derived plasma protein is essential for fertilization. Dev Cell. 2013;25(1):106–112. doi:10.1016/j.devcel.2013.03.001
   PubMed Web of Science ®Google Scholar
• Floehr J, Dietzel E, Schmitz C, et al. Down-regulation of the liver-derived plasma protein fetuin-B mediates reversible female infertility. MHR Basic Sci Reprod Med. 2016;23:1–11.
   Google Scholar
• Lin Y-H, Franc V, Heck AJ. Similar albeit not the same: in-depth analysis of proteoforms of human serum, bovine serum, and recombinant human fetuin. J Proteome Res. 2018;17(8):2861–2869. doi:10.1021/acs.jproteome.8b00318
   PubMed Web of Science ®Google Scholar
• Dabrowska AM, Tarach JS, Wojtysiak-Duma B, et al. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(3):352–359. doi:10.5507/bp.2015.018
   PubMed Web of Science ®Google Scholar
• Mori K, Emoto M, Inaba M. Fetuin-A and the cardiovascular system. Adv Clin Chem. 2012;56:176.
   Web of Science ®Google Scholar
• Braun-Falco O, Burgdorf W, Plewig G, et al. Braun-Falco´ s dermatology. Braun-Falcos Dermatol. 2009;2009:1712–xix.
   Google Scholar
• Adya KA, Inamadar AC, Palit A. Dermatoses with “Collarette of Skin”. BLDE; 2018.
   Google Scholar
• Krueger G, Ellis CN. Psoriasis—recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53(1):S94–S100. doi:10.1016/j.jaad.2005.04.035
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.339
   PubMed Web of Science ®Google Scholar
• Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49(2):44–50. doi:10.1016/S0190-9622(03)01134-4
   Web of Science ®Google Scholar
• Damiani G, Bragazzi NL, Aksut CK, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8. doi:10.3389/fmed.2021.743180
   Web of Science ®Google Scholar
• Egeberg A, Andersen YM, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort. BMJ open. 2019;9(3):e028116. doi:10.1136/bmjopen-2018-028116
   PubMed Web of Science ®Google Scholar
• Feldman SR, Tian H, Gilloteau I, et al. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective US database. BMC Health Serv Res. 2017;17(1):1–8. doi:10.1186/s12913-017-2278-0
   PubMed Web of Science ®Google Scholar
• Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–332. doi:10.1016/j.jaad.2017.10.012
   PubMed Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–1179. doi:10.1001/jamadermatol.2013.5015
   PubMed Web of Science ®Google Scholar
• Kimball A, Guerin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157–163. doi:10.1111/j.1468-3083.2010.03730.x
   PubMed Web of Science ®Google Scholar
• Kim N, Thrash B, Menter A, editors. Comorbidities in psoriasis patients. In: Seminars in Cutaneous Medicine and Surgery. Vol. 29. WB Saunders; 2010:10–15. doi:10.1016/j.sder.2010.01.002
   Google Scholar
• Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(suppl2):ii18–ii23. doi:10.1136/ard.2004.033217
   PubMed Web of Science ®Google Scholar
• Duarte GV, Follador I, Cavalheiro CMA, et al. Psoriasis and obesity: literature review and recommendations for management. An Bras Dermatol. 2010;85:355–360. doi:10.1590/S0365-05962010000300009
   PubMed Web of Science ®Google Scholar
• Huerta C, Rivero E, Rodríguez LAG. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559–1565. doi:10.1001/archderm.143.12.1559
   PubMedGoogle Scholar
• Uysal S, Yilmaz F, Karatoprak K, et al. The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. Eur Rev Med Pharmacol Sci. 2014;18(22):3453–3458.
   PubMed Web of Science ®Google Scholar
• Okan G, Baki AM, Yorulmaz E, et al. Serum visfatin, fetuin a, and pentraxin 3 levels in patients with psoriasis and their relation to disease severity. J Clin Lab Anal. 2016;30(4):284–289. doi:10.1002/jcla.21850
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Mondal SA, Kumar M, et al. Proinflammatory and antiinflammatory attributes of fetu Iν-A: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract. 2014;20(12):1345–1351. doi:10.4158/EP14421.RA
   PubMed Web of Science ®Google Scholar
• Wieduwilt M, Moasser M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566–1584. doi:10.1007/s00018-008-7440-8
   PubMed Web of Science ®Google Scholar
• Yano S, Banno T, Walsh R, et al. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin‐1. J Cell Physiol. 2008;214(1):1–13. doi:10.1002/jcp.21300
   PubMed Web of Science ®Google Scholar
• Furue K, Ito T, Tsuji G, et al. Autoimmunity and autoimmune comorbidities in psoriasis. Immunology. 2018;154(1):21–27. doi:10.1111/imm.12891
   PubMed Web of Science ®Google Scholar
• Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol. 2019;10:1764. doi:10.3389/fimmu.2019.01764
   PubMed Web of Science ®Google Scholar
• Ghazizadeh R, Shimizu H, Tosa M, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7(5):284. doi:10.7150/ijms.7.284
   PubMed Web of Science ®Google Scholar
• Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta dermatovenerologica Croatica. 2010;18(4):179.
   Web of Science ®Google Scholar
• Pietrzak A, Michalak-Stoma A, Chodorowska G, et al. Lipid disturbances in psoriasis: an update. Mediators Inflamm. 2010;2010:1–13. doi:10.1155/2010/535612
   Web of Science ®Google Scholar
• Khunger N, Gupta D, Ramesh V. Is psoriasis a new cutaneous marker for metabolic syndrome? A study in Indian patients. Indian J Dermatol. 2013;58(4):313. doi:10.4103/0019-5154.113958
   PubMedGoogle Scholar
• Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157(6):1249–1251. doi:10.1111/j.1365-2133.2007.08190.x
   PubMed Web of Science ®Google Scholar
• Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter real-life study in a cohort of Italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals. 2022;15(1):95. doi:10.3390/ph15010095
   Web of Science ®Google Scholar
• Damiani G, Franchi C, Pigatto P, et al. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents. World J Hepatol. 2018;10(2):329. doi:10.4254/wjh.v10.i2.329
   PubMed Web of Science ®Google Scholar
• Kridin K, Ludwig RJ, Schonmann Y, et al. The bidirectional association between bullous pemphigoid and psoriasis: a population-based cohort study. Front Med. 2020;7:511. doi:10.3389/fmed.2020.00511
   PubMed Web of Science ®Google Scholar
• Yuan Y, Qiu J, Lin ZT, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol. 2019;71(6):941–951. doi:10.1002/art.40830
   PubMed Web of Science ®Google Scholar
• Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5(1):1–16. doi:10.1038/ncomms6621
   Web of Science ®Google Scholar
• Pietrzak A, Chabros P, Grywalska E, et al. Serum lipid metabolism in psoriasis and psoriatic arthritis–an update. AMS. 2019;15(2):369. doi:10.5114/aoms.2018.74021
   Web of Science ®Google Scholar
• Damiani G, Radaeli A, Olivini A, et al. Increased airway inflammation in patients with psoriasis. 2016.
   Google Scholar
• Malerba M, Damiani G, Radaeli A, et al. Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol. 2015;173(6):1544–1545. doi:10.1111/bjd.13988
   PubMed Web of Science ®Google Scholar
• Fang HY, Liao WC, Lin CL, et al. Association between psoriasis and asthma: a population based retrospective cohort analysis. Br J Dermatol. 2015;172(4):1066–1071. doi:10.1111/bjd.13518
   PubMed Web of Science ®Google Scholar
• Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int. 2018;2018:1–10. doi:10.1155/2018/3140682
   Web of Science ®Google Scholar
• Kao L-T, Lee C-Z, Liu S-P, et al. Psoriasis and the risk of pneumonia: a population-based study. PLoS One. 2014;9(12):e116077. doi:10.1371/journal.pone.0116077
   PubMed Web of Science ®Google Scholar
• Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol. 2015;35(12):2667–2676. doi:10.1161/ATVBAHA.115.306460
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Rizzi M, et al. Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement. Clin Rheumatol. 2020;39(10):2981–2988. doi:10.1007/s10067-020-05050-2
   PubMed Web of Science ®Google Scholar
• Östling J, van Geest M, Schofield JP, et al. IL-17–high asthma with features of a psoriasis immunophenotype. J Allergy Clin Immunol. 2019;144(5):1198–1213. doi:10.1016/j.jaci.2019.03.027
   PubMed Web of Science ®Google Scholar
• Phillips BG, Wang Y, Ambati S, et al. Airways therapy of obstructive sleep apnea dramatically improves aberrant levels of soluble cytokines involved in autoimmune disease. Clin Immunol. 2020;221:108601. doi:10.1016/j.clim.2020.108601
   PubMed Web of Science ®Google Scholar
• Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159(2):342–350. doi:10.1111/j.1365-2133.2008.08655.x
   PubMed Web of Science ®Google Scholar
• Muse ED, Feldman DI, Blaha MJ, et al. The association of resistin with cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;239(1):101–108. doi:10.1016/j.atherosclerosis.2014.12.044
   PubMed Web of Science ®Google Scholar
• Pina T, Genre F, Lopez‐Mejias R, et al. Relationship of Leptin with adiposity and inflammation and Resistin with disease severity in Psoriatic patients undergoing anti‐TNF‐alpha therapy. J Eur Acad Dermatol Venereol. 2015;29(10):1995–2001. doi:10.1111/jdv.13131
   PubMed Web of Science ®Google Scholar
• Huang H, Shen E, Tang S, et al. Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids Health Dis. 2015;14(1):1–9. doi:10.1186/s12944-015-0039-9
   PubMed Web of Science ®Google Scholar
• Husni ME, Merola JF, Davin S, editors. The psychosocial burden of psoriatic arthritis. In: Seminars in Arthritis and Rheumatism. Elsevier; 2017.
   Google Scholar
• Demirbaş A, Kurtipek GS, Tunçez A, et al. The role of cystatin C and fetuin A in the determination of early atherosclerotic risk in psoriasis patients. Dermatol Ther. 2020;33(6):e13898. doi:10.1111/dth.13898
   PubMed Web of Science ®Google Scholar
• Borsky P, Fiala Z, Andrys C, et al. C-reactive protein, chemerin, fetuin-A and osteopontin as predictors of cardiovascular risks in persons with psoriasis vulgaris. Physiol Res. 2021;383–391. doi:10.33549/physiolres.934654
   PubMed Web of Science ®Google Scholar
• Genc M, Can M, Guven B, et al. Evaluation of serum Fetuin-a and Osteoprotegerin levels in patients with psoriasis. Ind J Clin Biochem. 2017;32(1):90–94. doi:10.1007/s12291-016-0570-0
   PubMed Web of Science ®Google Scholar
• Gulle S, Ozturk S, Kozaci LD, et al. Fetuin-A and its association with disease activity in psoriatic arteritis/Fetuin-A ve psoriyatik artrit hastalik aktivitesi ile iliskisi. J Turk Soc Rheumatol. 2021;13(2):47–54.
   Google Scholar
• Shehata W, Basha M, Gayed I, et al. Relationship between disease severity and fetuin-A levels in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2020;86(5):586. doi:10.4103/ijdvl.IJDVL_355_19
   PubMed Web of Science ®Google Scholar
• Agamia NF, Ae-a AF, El-Hadidy A, et al. YKL-40, fetuin-A plasma levels, and carotid intima-media thickness: do they have relations with subclinical atherosclerosis associated with psoriasis and the disease severity? J Egypt Womens Dermatol Soc. 2019;16(2):133. doi:10.4103/JEWD.JEWD_23_19
   Google Scholar
• Gerdes S, Osadtschy S, Buhles N, et al. Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol. 2014;23(5):322–325. doi:10.1111/exd.12381
   PubMed Web of Science ®Google Scholar
• Ataseven A, Kesli R, Akyurek F, et al. Decreased serum levels of alpha-2-Heremans Schmid glycoprotein (fetuin-a) in patients with psoriasis. Aperito J Dermatol. 2015;2:111.
   Google Scholar
• Tuttolomondo A, Di Raimondo D, Di Sciacca R, et al. Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis. 2010;208(1):290–296. doi:10.1016/j.atherosclerosis.2009.07.032
   PubMed Web of Science ®Google Scholar
• Falquerho L, Paquereau L, Vilarem MJ, et al. Functional characterization of the promoter of pp63, a gene encoding a natural inhibitor of the insulin receptor tyrosine kinase. Nucleic Acids Res. 1992;20(8):1983–1990. doi:10.1093/nar/20.8.1983
   PubMed Web of Science ®Google Scholar
• Flisiak I, Zaniewski P, Rogalska M, et al. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine. 2010;52(3):225–229. doi:10.1016/j.cyto.2010.09.012
   PubMed Web of Science ®Google Scholar
• Flisiak I, Zaniewski P, Rogalska‐Taranta M, et al. Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations. J Eur Acad Dermatol Venereol. 2012;26(3):302–307. doi:10.1111/j.1468-3083.2011.04053.x
   PubMed Web of Science ®Google Scholar
• Uyar B, Akyıldız M, Solak A, et al. Relationship between serum fetuin-A levels and carotid intima-media thickness in Turkish patients with mild to moderate psoriasis. A case-control study. Acta Dermatovenerologica Croatica. 2015;23(3):171.
   PubMed Web of Science ®Google Scholar
• Grochowiec M, Narbutt J, Lesiak A. Serum concentration of endocan, fetuin-A, and endothelin in plaque psoriasis-coincidence or fate? A preliminary study. Dermatol Rev/Przeglad Dermatol. 2021;108(1):16–26.
   Google Scholar
• Li W, Zhu S, Li J, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One. 2011;6(2):e16945. doi:10.1371/journal.pone.0016945
   PubMed Web of Science ®Google Scholar
• Wang XQ, Hung BS, Kempf M, et al. Fetuin‐A promotes primary keratinocyte migration: independent of epidermal growth factor receptor signalling. Exp Dermatol. 2010;19(8):e289–e92. doi:10.1111/j.1600-0625.2009.00978.x
   PubMed Web of Science ®Google Scholar
• Yang SJ, Hong HC, Choi HY, et al. Effects of a three‐month combined exercise programme on fibroblast growth factor 21 and fetuin‐A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011;75(4):464–469. doi:10.1111/j.1365-2265.2011.04078.x
   PubMed Web of Science ®Google Scholar
• Jüllig M, Yip S, Xu A, et al. Lower fetuin-A, retinol binding protein 4 and several metabolites after gastric bypass compared to sleeve gastrectomy in patients with type 2 diabetes. PLoS One. 2014;9(5):e96489. doi:10.1371/journal.pone.0096489
   PubMed Web of Science ®Google Scholar
• Laughlin GA, McEvoy LK, Barrett Connor E, et al. Fetuin‐A, a new vascular biomarker of cognitive decline in older adults. Clin Endocrinol (Oxf). 2014;81(1):134–140. doi:10.1111/cen.12382
   PubMed Web of Science ®Google Scholar
• Fiore CE, Celotta G, Politi GG, et al. Association of high alpha2-Heremans–Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis. 2007;195(1):110–115. doi:10.1016/j.atherosclerosis.2006.08.052
   PubMed Web of Science ®Google Scholar
• Emoto M, Mori K, Lee E, et al. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010;59(6):873–878. doi:10.1016/j.metabol.2009.10.005
   PubMed Web of Science ®Google Scholar
• Szweras M, Liu D, Partridge EA, et al. α2-HS glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem. 2002;277(22):19991–19997. doi:10.1074/jbc.M112234200
   PubMed Web of Science ®Google Scholar
• Roos M, Oikonomou D, von Eynatten M, et al. Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol. 2010;9(1):1–7. doi:10.1186/1475-2840-9-48
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Yonal O, Kurt R, et al. Serum fetuin A/α 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem. 2010;47(6):549–553. doi:10.1258/acb.2010.010169
   PubMed Web of Science ®Google Scholar
• Kalabay L, Jakab L, Prohászka Z, et al. Human fetuin/α2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol. 2002;14(4):389–394. doi:10.1097/00042737-200204000-00009
   PubMed Web of Science ®Google Scholar
• Ix JH, Chertow GM, Shlipak MG, et al. Fetuin-A and kidney function in persons with coronary artery disease—data from the Heart and Soul Study. Nephrol Dial Transplant. 2006;21(8):2144–2151. doi:10.1093/ndt/gfl204
   PubMed Web of Science ®Google Scholar
• Ochieng J, Nangami G, Sakwe A, et al. Impact of Fetuin-A (AHSG) on tumor progression and type 2 diabetes. Int J Mol Sci. 2018;19(8):2211. doi:10.3390/ijms19082211
   PubMed Web of Science ®Google Scholar
• Inoue K, Wada J, Eguchi J, et al. Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray. PLoS One. 2013;8(10):e77118. doi:10.1371/journal.pone.0077118
   PubMed Web of Science ®Google Scholar
• Harris VK, Donelan N, Yan QJ, et al. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Multiple Scleros J. 2013;19(11):1462–1472. doi:10.1177/1352458513477923
   PubMed Web of Science ®Google Scholar
• Minas M, Mystridou P, Georgoulias P, et al. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD. 2013;10(1):28–34. doi:10.3109/15412555.2012.727922
   PubMedGoogle Scholar
• Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(11):4479–4485. doi:10.1210/jc.2008-1505
   PubMed Web of Science ®Google Scholar
• Robinson KN, Teran-Garcia M. From infancy to aging: biological and behavioral modifiers of fetuin-A. Biochimie. 2016;124:141–149. doi:10.1016/j.biochi.2015.12.016
   PubMed Web of Science ®Google Scholar
• Rudd PM, Dwek RA. Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol. 1997;32(1):1–100. doi:10.3109/10409239709085144
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50. doi:10.1146/annurev.immunol.25.022106.141702
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427. doi:10.3390/ijms18112427
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Phung M, et al. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78(5):1019–1020. doi:10.1016/j.jaad.2017.11.036
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790. doi:10.1111/jdv.14114
   PubMed Web of Science ®Google Scholar
• Daudén E, Puig L, Ferrándiz C, et al. Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2016;30:1–18. doi:10.1111/jdv.13542
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi:10.1007/s00403-010-1080-1
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nobeyama Y, Hayashi M, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40(12):1008–1013. doi:10.1111/1346-8138.12353
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Investig Dermatol. 2015;135(11):2632–2640. doi:10.1038/jid.2015.208
   PubMed Web of Science ®Google Scholar
• Damiani G, Conic RR, de Vita V, et al. When IL‐17 inhibitors fail: real‐life evidence to switch from secukinumab to Adalimumab or ustekinumab. Dermatol Ther. 2019;32(2):e12793. doi:10.1111/dth.12793
   PubMed Web of Science ®Google Scholar
• Hu Y, Chen Z, Gong Y, et al. A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis. Clin Drug Investig. 2018;38(3):191–199. doi:10.1007/s40261-017-0603-3
   PubMed Web of Science ®Google Scholar
• Damiani G, Conic RR, Pigatto PD, et al. From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management. Dermatol Ther. 2019;32(3):e12886. doi:10.1111/dth.12886
   PubMed Web of Science ®Google Scholar
• Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279–1285. doi:10.1038/nm.2851
   PubMed Web of Science ®Google Scholar
• Jung TW, Youn B-S, Choi HY, et al. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. Biochem Pharmacol. 2013;86(7):960–969. doi:10.1016/j.bcp.2013.07.034
   PubMed Web of Science ®Google Scholar
• Öner-iyidoğan Y, Kocak H, Seyidhanoğlu M, et al. Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet. J Physiol Biochem. 2013;69(4):677–686. doi:10.1007/s13105-013-0244-9
   PubMed Web of Science ®Google Scholar
• Price PA, Williamson MK, Nguyen TMT, et al. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem. 2004;279(3):1594–1600. doi:10.1074/jbc.M305199200
   PubMed Web of Science ®Google Scholar